Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
about
Risk definition and management strategies in retinoblastoma: current perspectivesA phase I dose escalation of combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with neuroblastoma.Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular RetinoblastomaPhase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group studyA phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-term follow-upDouble high-dose chemotherapy and stem cell transplantation in adult Wilms' tumor.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma.Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.Chronic neuroblastoma.Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
P2860
Q26849675-41537303-6D1F-49BB-9A3E-9F0C5317F8E7Q33332916-CF929AE8-E521-42BF-AB0A-09DEFF7538EEQ33437979-B7BC2353-FA84-4E12-A08F-755BA8ABD578Q34131807-22A9CE1D-5345-44C2-9C5D-C6CF2D8EE35EQ35565630-7FE88A55-7759-4997-ADDA-796051FA0FD5Q36970948-EDC591B9-D7F9-4966-A337-6FFCA009F7C5Q37818231-5FE3BD0F-8B66-42ED-A355-8A61415B4609Q38113988-105A4578-0CC0-4DF7-ABD2-3089C8D3F395Q38791215-A498177B-734F-4520-A6CB-9C56784BC728Q38961012-60B5D967-19B7-4082-ABEB-F55B65B1BEF3Q40808258-10DC9590-4525-4447-B736-26A40D3738BAQ41733479-3E80B9E4-BA3A-4C61-8D68-555B779AC8C0Q43770759-269CCAB9-DB1A-41BA-AF64-B5BABA04BCCDQ44128430-7A31FC27-A567-4324-A3B2-BFA0B461AA69Q44523074-1F814DB1-D5D4-46E9-B488-2C9564A1BEAAQ46884985-B7684C30-57DB-41C6-B10A-F7DE27C89981Q53657080-7A48A205-8349-4F0A-985F-BEBDB0F8C99CQ55474881-7C63FAE6-700F-4EE6-B5E6-0BDC5E654617
P2860
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մարտին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@ast
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@en
type
label
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@ast
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@en
prefLabel
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@ast
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@en
P2093
P1476
Phase I study of topotecan in ...... ediatric Oncology Group Study.
@en
P2093
C F Stewart
R L Saylors
T J Vietti
W C Zamboni
P304
P356
10.1200/JCO.1998.16.3.945
P407
P577
1998-03-01T00:00:00Z